Running Point Capital Advisors’s Solid Biosciences SLDB Stock Holding History

Running Point Capital Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-667	Closed	-$5K	–	229
2022 Q3	$5K	Hold	667	–	–	﹤0.01%	206
2022 Q2	$6K	Hold	667	–	–	﹤0.01%	211
2022 Q1	$12K	Buy	+667	New	+$11.8K	0.01%	200

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Alyeska Investment Group

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Running Point Capital Advisors's SLDB Position: Q4 2022 in Review

Running Point Capital Advisors sold out of Solid Biosciences (SLDB) in Q4 2022, closing a stake of 667 shares — an estimated $5K sold.

Running Point Capital Advisors first reported a position in SLDB in Q1 2022 and held it in 3 quarters. The position peaked at $12K in Q1 2022. 35 funds tracked by Wall St. Rank hold SLDB as of Q4 2022.

Running Point Capital Advisors reported no remaining Solid Biosciences position as of Q4 2022 after selling out during the quarter.
Running Point Capital Advisors sold 667 Solid Biosciences shares in Q4 2022, an estimated $5K.
Running Point Capital Advisors first reported a position in Solid Biosciences in Q1 2022 and held it in 3 quarters.
Running Point Capital Advisors's Solid Biosciences position peaked at $12K in Q1 2022.
35 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2022.

Based on Running Point Capital Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.